Enlivex ENLV 深 沪
交易中 07-02 10:23:00 美东时间
0.5574
+0.016
+2.92%
华盛通- 最 高0.5595
- 今 开0.5404
- 成交量 8.62万股
- 最 低 0.54
- 昨 收 0.5416
- 总市值 1.34亿
- 52周最高 2.10
- 市盈率 静 0.02
- 换手率 0.04%
- 52周最低 0.5246
- 委 比 -33.33%
- 总股本 2.41亿
- 历史最高 44.90
- 量 比 2.26
- 振 幅 3.60%
- 历史最低 0.5246
- 每 手 1
- 风险率 0.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Enlivex Holds 79.569B RAIN Token With Total Value Of ~$1.14B
Enlivex Ltd. (NASDAQ:ENLV, "Enlivex" or the "Company")), a quality longevity company powered by a prediction markets treasury, today provided an update on its RAIN token holdings. As of June 20, 2026, the Company held 79,568,550,005 RAIN tokens with a total value of approximately $1.14 billion.
06-22 20:54
Enlivex Receives Australian Patent Entitled 'Therapeutic Apoptotic Cells For Treatment Of Osteoarthritis'
The patent will provide Enlivex with added intellectual property protection in Australia through at least 2040 with claims covering methods of using Allocetra™ to treat subjects with osteoarthritis. With this issuance, the Company has secured patent protection for Allocetra™ in osteoarthritis in an ...
06-15 20:04
Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis
Enlivex Ltd. has secured a new Australian patent for Allocetra™, a therapeutic immunotherapy targeting osteoarthritis, providing protection through 2040. The company recently initiated a Phase 2b clinical trial for Allocetra™ in knee osteoarthritis, following positive earlier-stage results. Knee osteoarthritis affects millions globally, with limited treatment options, highlighting the need for innovative therapies. Enlivex combines therapeutic de...
06-15 12:00
Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity
Enlivex Ltd. highlights Rain's $100 million liquidity commitment, positioning it as the third-largest prediction market protocol globally with $450 million in TVL, alongside Polymarket and Kalshi. Enlivex holds 79.57 billion RAIN tokens worth $919 million and has an option to acquire up to 271.37 billion tokens until Dec. 31, 2027, valued at $2.23 billion. Shai Novik, Enlivex's Executive Chairman, emphasizes Rain's growth potential and validates ...
05-27 12:00
EnLivex Doses First Patient In Its Phase 2b Clinical Trial Of Allocetra For Treatment Of Patients With Moderate-to-Severe Age-Related Symptomatic Primary Knee Osteoarthritis
The global, multicenter, randomized, double-blind, placebo-controlled Phase 2b clinical trial is designed to evaluate the efficacy and safety of intra-articular injections of Allocetra™ in patients with
05-18 20:03
Enlivex receives Nasdaq non-compliance notice over sub-$1 share price
Enlivex(ENLV) was notified by Nasdaq that its share price stayed below the $1 minimum bid requirement for 30 consecutive business days. The company has until November 9, 2026, to regain compliance. I...
05-16 04:16
Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification
Enlivex Ltd. (Nasdaq: ENLV) received a notice from Nasdaq stating its ordinary shares closed below the $1.00 minimum bid price requirement over 30 consecutive business days. The company has 180 days until November 9, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. If unsuccessful, it may qualify for an additional 180-day period to demonstrate compliance. Failure to meet requirement...
05-15 20:10
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Psyence Biomedical (NASDAQ:PBM) shares increased by 63.4% to $9.59 dur...
04-17 05:05
美股大行评级 | 高盛首予PayPay“买入”评级；神经分泌生物科学获花旗等多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从13美元升至20美元；韦德布什：维持FuboTV"跑赢大市"评级，目标价从3.5美元升至24美元
04-08 18:35
